Pharma Deals Review, Vol 2009, No 1 (2009)

Font Size:  Small  Medium  Large

ZymoGenetics in Blockbuster Deal with BMS

Taskin Ahmed

Abstract


Bristol-Myers Squibb signed a US$1.1 B deal to co-develop ZymoGenetics’ PEG-interferon lambda, a hepatitis C drug, which is in early clinical trials. ZymoGenetics needed a deal of this size for its survival whereas Bristol-Myers had to strengthen its hepatitis C pipeline.

Full Text: pdf html

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.